New Subgroup Analysis of the Phase 3 OPTIMUM Study Demonstrates the Benefits of PONVORYTM (ponesimod) Over teriflunomide in Early Disease Multiple Sclerosis
- EMEA Innovative Medicine
- New Subgroup Analysis of the Phase 3 OPTIMUM Study Demonstrates the Benefits of PONVORYTM (ponesimod) Over teriflunomide in Early Disease Multiple Sclerosis
New Subgroup Analysis of the Phase 3 OPTIMUM Study Demonstrates the Benefits of PONVORYTM (ponesimod) Over teriflunomide in Early Disease Multiple Sclerosis
- X (Twitter)
Copy link